Unique Parallel Peptide Synthesizer with Automated Microwave Technology Offers "the Best of Both Worlds" for Peptide Chemists
Share:
Uppsala, Sweden - Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the eagerly awaited global launch of the Syro Wave(TM); its new microwave and parallel peptide synthesizer. The Syro Wave(TM) is a result of the joint development project announced last year between Biotage and MultiSynTech. It combines the proven performance of the established MultiSynTech robotic synthesizer with Biotage microwave technology.
The Syro Wave(TM) peptide synthesis system is the only system on the market that offers both microwave and parallel peptide synthesis capabilities. To date peptide synthesis labs have been required to invest in both standalone parallel systems for productivity and cost efficiency, and standalone microwave systems for difficult or longer peptides. This results in increased demand on bench space, duplication of computer control systems, and multiple operating software platforms for chemists to learn and maintain. Biotage has addressed these shortcomings with the Syro Wave(TM), containing both parallel and microwave technologies on the same platform.
The new Biotage Syro Wave(TM) increases productivity, yield and purity while cutting costs and saving time. "At Biotage the focus is on developing technology to speed up and simplify experimental procedures while simultaneously driving down operating costs. Whether the customer is a Pharma development group, a CRO focused on cost and productivity or an Academic researcher focused on unique sequences, the Syro Wave(TM) fits," noted Scott Carr, Vice President Commercial Operations, Biotage.
For more information on the Biotage parallel Peptide Synthesizer system, please email product_info@biotage.com or visit www.biotage.com
About Biotage
Biotage is a global technology based company, which provides tools for life science research. The company offers a broad range of solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world's top 30 pharmaceutical companies, the world's top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala, Sweden and has subsidiaries in the United States, United Kingdom and Japan. Biotage has 270 employees and had sales of SEK 385,3m in 2008. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: www.biotage.com
